Compare ATO & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATO | RMD |
|---|---|---|
| Founded | 1906 | 1989 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9B | 33.2B |
| IPO Year | 1994 | N/A |
| Metric | ATO | RMD |
|---|---|---|
| Price | $181.17 | $226.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $173.63 | ★ $293.70 |
| AVG Volume (30 Days) | ★ 902.8K | 843.4K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.16% | 1.05% |
| EPS Growth | ★ 9.22 | N/A |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $4,702,755,000.00 | N/A |
| Revenue This Year | $15.74 | $10.64 |
| Revenue Next Year | $11.26 | $7.38 |
| P/E Ratio | $75.85 | ★ $25.61 |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $141.59 | $199.92 |
| 52 Week High | $190.13 | $293.81 |
| Indicator | ATO | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 28.86 |
| Support Level | $163.67 | N/A |
| Resistance Level | $187.98 | $260.21 |
| Average True Range (ATR) | 3.03 | 4.93 |
| MACD | -0.87 | -2.38 |
| Stochastic Oscillator | 7.58 | 4.61 |
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.